Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of
Go back to Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of| (NASDAQ: PRAX) | Delayed: 351.81 -3.34 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $355.15 | 52 Week High | $ | |||
| Open | $352.99 | 52 Week Low | $ | |||
| Day High | $357.50 | P/E | N/A | |||
| Day Low | $349.82 | EPS | $ | |||
| Volume | 175,356 | |||||
